TNFRSF8 and Hodgkins lymphoma: Since anti-CD30 antibodies are not tumour-specific and may target reactive T and B cell subsets [14,15], the creation of antibodies against HL-specific cell surface targets that are not activation-associated markers remains a desirable goal.